Summary AQ4N (1,4-bis-{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9,10-dione) is a novel bioreductive agent that can be reduced to a stable, DNA-affinic The presence of hypoxic cells within tumours is thought to be a major cause of treatment failure following radiotherapy (Bush et al., 1978; Okunieff et al., 1993) . Bioreductive drugs specifically target these radioresistant cells since they are administered as a non-toxic prodrug that is reduced in a lowoxygen environment to an active cytotoxic product (Workman and Stratford, 1993) . We have developed a novel compound AQ4N (1,4 -bis -{[2 -(dimethylamino -N -oxide)-ethyl]amino}5,8-dihydroxyanthracene-9,10-dione), which can be reduced in a hypoxic environment to a stable DNA-affinic agent AQ4 (1,4-bis-{[2-(dimethylamino)ethyl}amino}5,8-dihydroxyanthracene-9,10-dione). Reduction of the two N-oxide side chains of the electrically neutral AQ4N leads to the formation of two positively charged alkylamino side chains (Figure 1 ). These interact electrostatically with DNA, resulting in a highly significant level of AQ4 binding (Patterson, 1993) and account for several distinct differences in the properties of AQ4 as compared with AQ4N (Table I) . It should be noted that AQ4 is a structural analogue of the cancer chemotherapeutic agent mitoxantrone, which has been shown to have a high affinity for DNA. Both compounds are also known to inhibit topoisomerase II (Patterson, 1993; Desnoyes et al., 1993) .
The presence of hypoxic cells within tumours is thought to be a major cause of treatment failure following radiotherapy (Bush et al., 1978; Okunieff et al., 1993) . Bioreductive drugs specifically target these radioresistant cells since they are administered as a non-toxic prodrug that is reduced in a lowoxygen environment to an active cytotoxic product (Workman and Stratford, 1993) . We have developed a novel compound AQ4N (1,4 -bis -{[2 -(dimethylamino -N -oxide)-ethyl]amino}5,8-dihydroxyanthracene-9,10-dione), which can be reduced in a hypoxic environment to a stable DNA-affinic agent AQ4 (1,4-bis-{[2-(dimethylamino)ethyl}amino}5,8-dihydroxyanthracene-9,10-dione). Reduction of the two N-oxide side chains of the electrically neutral AQ4N leads to the formation of two positively charged alkylamino side chains ( Figure 1 ). These interact electrostatically with DNA, resulting in a highly significant level of AQ4 binding (Patterson, 1993) and account for several distinct differences in the properties of AQ4 as compared with AQ4N (Table I) . It should be noted that AQ4 is a structural analogue of the cancer chemotherapeutic agent mitoxantrone, which has been shown to have a high affinity for DNA. Both compounds are also known to inhibit topoisomerase II (Patterson, 1993; Desnoyes et al., 1993) .
In the present study, we have used the alkaline single cell gel electrophoresis assay (comet assay) to evaluate DNA damage in T50/80 tumour cells exposed to AQ4N in vivo and ex vivo. The alkaline comet assay, based on the method of Singh et al. (1988) , is used to detect single-strand breaks in DNA following disruption of the DNA by exposure to high pH. During electrophoresis the broken/unwound DNA streams away from the undamaged DNA and is observed as a 'comet' tail. Unlike other assays (Whitaker et al., 1991) , the comet assay allows the detection and quantitation of DNA damage in individual cells. It has been used in a variety of situations to measure DNA damage and repair (McKelvey-Martin et al., 1993; Olive, 1994) , with a sensitivity greater than or equal to other methods that are currently available (Olive et al., 1990) .
Our earlier studies with T50/80 tumour-bearing mice have shown that AQ4N (200 mg kg-1) significantly enhanced the tumour growth delay caused by radiation. This occurred when radiation was administered both as a single dose (12 Gy) and in a multifraction regimen (5 x 3 Gy). A study of the scheduling of AQ4N administration showed that there was a very long time period over which a maximal effect could be elicited (drug given 4 days before to 6 h after radiation). These results suggest that AQ4N has significant potential as a bioreductive drug (McKeown et al., 1995) . In the present study the comet assay was used to evaluate in more detail the mechanism of these interactions.
Materials and methods

Tumour model
These experiments were carried out using early passages (4-14) of the poorly differentiated T50/80 murine mammary carcinoma. This first arose in a female BDF mouse mammary gland; details of the derivation and maintenance have been published previously (Moore, 1988) . Tumours were induced on the rear dorsum of 8-to 12-week-old male B6D2F1 mice using 0.05 ml of tumour brei prepared from a donor mouse.
Ex vivo protocol Untreated T50/80 tumours (6.5-9.0 mm geometric diameter, GMD) were excised and gently disaggregated by mechanical disruption in ice-cold phosphate-buffered saline (PBS). Single cell suspensions were prepared by filtration through a 40 gum mesh. These were then centrifuged and resuspended in Eagle's minimal essential medium (EMEM) containing 10% fetal calf serum (FCS) at a concentration of 106 cells ml-'. Cells (20 ml) were placed in 125 ml rubber sealed glass bottles. These were gassed for 2 h at 37°C to provide welloxygenated conditions, i.e. 95% air/5% carbon dioxide or hypoxic conditions 95% nitrogen/5% carbon dioxide. AQ4N (20 gM) was added for the last 90 min of this period by injection through the sealed lid. (Figure 2a) . When AQ4N was present under aerobic conditions a very small number of cells showed damage. This was only observed at relatively long times after exposure to drug (24-96 h) (Figure 2b ). Under hypoxic conditions almost no DNA damage was observed in the absence of AQ4N, although a very small number did show severe damage at longer intervals after hypoxic exposure (Figure 2c ). When cells were exposed to AQ4N with hypoxia an increasing level of DNA damage was observed from 24 to 96 h. 502 almost all cells analysed had some damage, with many being severely damaged (Figure 2d ). This suggests that the T50/80 tumour can metabolise AQ4N to a cytotoxic compound, which may be AQ4 (see Figure 1) . AQ4N alone had only a small effect on the tumour at all time points studied (Figure 4b However by 24 h the proportion of damaged cells had begun to increase and this became more extensive by 72-120 h following exposure to radiation. By this time many of the cells showed moderate to severe DNA damage, whereas tumours exposed to radiation alone had only low levels of severely damaged cells at these later time points. Discussion AQ4N can be reduced to AQ4 by exogenous liver microsomes but is poorly reduced by several established cell lines (Patterson, 1993 (Patterson, , 1994 . It is proposed that the insensitivity of in vitro cells may be due to a lack of the appropriate enzyme(s) necessary for the reduction of AQ4N, since reduction does occur when freshly prepared liver microsomes are present. This does not exclude the possibility that AQ4N is reduced in vivo, since it is well recognised that enzyme profiles change when cells are transferred to a tissue culture environment (Collard et al., 1985; Krupski et al., 1985) . Studies in a range of murine models (Cole, private communication; McKeown et al., 1995) would support the proposition that AQ4N is metabolised in vivo to a cytotoxic compound. The current series of studies was designed to further explore this hypothesis. Initially we used excised T50/80 tumour cell suspensions and examined their ability to metabolise AQ4N under hypoxic conditions in vitro (Figure 2a-d) . Our results show that AQ4N remained almost completely inactive under oxic conditions despite being taken up into the cells. Under hypoxic conditions, AQ4N was modified to a DNAdamaging agent, which had increasing effectiveness from 24 h after the initial exposure. It is suggested that the cytotoxic agent formed is AQ4, since this is the only known reduction product of AQ4N and it is formed under reducing conditions on a mole for mole basis (Patterson, 1993) . The relatively long time interval (greater than 18 h) between exposure to hypoxia and appearance of DNA toxicity suggests that the active cytotoxic agent was not directly damaging to the DNA but caused interference in the ability of the cell to function. This is consistent with the evidence that AQ4 (not AQ4N) causes topoisomerase II inhibition, a process which interferes with cell cycle progression by accumulation of cells in G2/M (Desnoyes et al., 1993; PJ Smith, personal communication) . The extent of damage suggests a major disruption to cellular metabolism and may even indicate that apoptosis is being initiated in compromised cells. Previously Olive and Banath (1992) have shown that the topoisomerase II inhibitor etoposide is much more toxic to cycling cells than non-cycling cells. Our results are consistent with their observation.
The oxygen-dependent cytotoxicity of AQ4N is lost within 24 h of tumour excision (Figure 3a-d) despite the evidence of the drug being taken up into the cells. This observation helps to explain the limited ability of established cell lines to reduce AQ4N in vitro. It also suggests that in vitro testing of chemotherapy drugs that require intratumoral enzymic activation may on some occasions give misleading results, since the enzyme profile (among other factors) may be critically changed in the tissue culture environment. Falsepositive and negative results may both result from this phenomenon.
We have previously shown that AQ4N has bioreductive potential in vivo (McAleer et al., 1992) and, when combined with radiation, AQ4N shows an interaction that is at least additive (McKeown et al., 1995) . We therefore examined the extent of DNA damage caused when AQ4N, with or without radiation, was injected before tumour excision (Figure 4) . Control tumours showed little evidence of DNA damage following excision. Also tumours treated with AQ4N alone showed only a minimal number of damaged cells at any time point examined. As expected a significant level of DNA damage was observed in cells prepared from tumours excised immediately after a single dose of radiation (Figure 4c treatment, suggesting that this effect is present in vivo for at least this length of time. Since it is known that AQ4N can be reduced under hypoxic conditions to the stable compound AQ4, one explanation for the observed effect is the oxygen-dependent production of the DNA-affinic metabolite AQ4, which remains bound to the DNA in the hypoxic cells for many hours/days. A further advantage of the production of a stable DNA-affinic cytotoxic agent is the ability of the agents, once generated, to kill cells at any level of oxygenation. Even if the drug diffuses from the original site of production its high affinity for DNA will allow its effect to be exerted on neighbouring cells.
In conclusion, this study shows that the cytotoxicity of AQ4N is oxygen dependent and can affect T50/80 tumour cells for at least 4 days after exposure to hypoxia. This is consistent with the results of previous in vivo experiments using tumour growth delay as the end point (McKeown et al., 1995) . The loss of the oxygen-dependent sensitivity to AQ4N within 24 h of tumour excision provides evidence for critical changes to tumour cell sensitivity following transfer to culture. Use of the comet assay to immediately test excised tumours with cytotoxic agents requiring in vivo metabolism may provide a more appropriate method for determining in vivo efficacy than the testing of putative cytotoxic agents against panels of established tissue culture cell lines.
